Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) announced that its management team will participate in two investor events: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference/b on , and Canaccord Genuity's 46th Annual Growth Conference with a presentation on Tuesday, August 11, 2026 from 3:30–3:55 PM ET. A live webcast of the Canaccord presentation will be available via the Investors section of the company’s website at www.angiodynamics.com.
AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 Q4 pro forma net sales of $86.6 million, up 8.0% year over year, with Med Tech sales up 16.7% to $41.8 million and Med Device sales up 1.1% to $44.8 million. Q4 GAAP gross margin was 54.0%, GAAP loss per share was $0.27, adjusted loss per share $0.07, and adjusted EBITDA $3.3 million.
For fiscal 2026, pro forma net sales grew 9.4% to $320.2 million, with Med Tech up 18.4% to $150.0 million and Med Device up 2.5% to $170.2 million. Full-year GAAP loss per share was $0.88, adjusted loss per share $0.24, and adjusted EBITDA $13.2 million. Gross margin rose to 54.6%, and AngioDynamics ended the year with $53.9 million in cash and no debt. The company highlighted NanoKnife clinical and reimbursement milestones, multiple FDA IDE approvals, and issued fiscal 2027 guidance for net sales of $336–$341 million, Med Tech growth of 12–15%, and adjusted EPS of ($0.29)–($0.24).
AngioDynamics (NASDAQ: ANGO) will release its fiscal 2026 fourth quarter and full-year financial results before market open on Tuesday, July 14, 2026. Management will host a conference call at 8:00 a.m. ET, with live webcast and replay available via the company’s investor website.
AngioDynamics (NASDAQ:ANGO) received FDA Investigational Device Exemption (IDE) approval to begin the RELIEF feasibility study evaluating its NanoKnife irreversible electroporation (IRE) platform as a minimally invasive, tissue-sparing treatment for benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms.
The prospective, single-arm study will enroll 40 men at up to five U.S. sites, assessing symptom relief and safety over six months, with secondary endpoints followed for five years.
AngioDynamics (NASDAQ: ANGO) announced that Palmetto GBA issued final Local Coverage Determination LCD L40205, effective July 5, 2026, establishing Medicare coverage guidance for irreversible electroporation (IRE) with NanoKnife in favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver.
Category I CPT codes for prostate and liver IRE became active January 1, 2026, supporting standardized billing. The LCD applies in Palmetto’s Jurisdictions J and M and aligns with major clinical guidelines, potentially expanding reimbursed access to NanoKnife IRE for eligible patients.
AngioDynamics (NASDAQ:ANGO) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 9:20 a.m. ET.
A live webcast and replay will be available in the Investors section of the company website.
AngioDynamics (NASDAQ: ANGO) reported 24‑month data from the pivotal U.S. PRESERVE trial of its NanoKnife IRE System in intermediate-risk prostate cancer. Results showed 0 new treatment failures between 12–24 months, 97% of patients with PSA below baseline, 94.4% 24‑month completion, and no new device- or procedure-related adverse events.
AngioDynamics (NASDAQ: ANGO) reported fiscal Q3 FY2026 net sales of $78.4M (+8.9% pro forma) and Med Tech sales $37.3M (+19%). GAAP net loss was $8.1M (loss per share $0.19); adjusted loss per share was $0.07 and adjusted EBITDA was $1.8M. Cash at quarter end was $37.8M. The company raised FY2026 guidance to $313.5–$315.5M net sales and $10.0–$12.0M adjusted EBITDA, while noting a full‑year tariff impact of $4–$6M and a planned $3–$5M inventory build that may slightly push FY cash flow negative.
AngioDynamics (NASDAQ: ANGO) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 8:45 a.m. ET. A live webcast will be available via the company’s Investors website and will be posted for replay after the event.
AngioDynamics (NASDAQ: ANGO) will report fiscal 2026 third quarter results before market open on April 2, 2026. Management will host a conference call at 8:00 AM ET the same day and a live webcast will be available in the Investors section of the company website.
Replay and a recorded telephone playback will be available after the call; the recorded telephone playback is accessible until April 9, 2026 at 11:59 PM ET.